Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings –– Ongoing pivotal trial and FDA Type C meeting provide clear path to potential sevasemten registration as the first ever therapy for Becker –– Encouraging Phase 2 observations in Duchenne define the dose and inform design for Phase 3 –– Edgewise leadership to discuss these updates on Thursday, June 26 at 8:30 a.m. Eastern Time at a virtual investor event –BOULDER, Colo., June ...